Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Health care worker data. by Kevin Guzman (16474985)

“…<div><p>Digital adherence technologies (DATs) have emerged as an alternative to directly observed therapy (DOT) for supervisions of tuberculosis (TB) treatment. We conducted a meta-analysis of implementation feedback obtained from people with TB and health care workers (HCWs) involved in TB REACH Wave 6-funded DAT evaluation projects. …”

People with TB data. by Kevin Guzman (16474985)

“…<div><p>Digital adherence technologies (DATs) have emerged as an alternative to directly observed therapy (DOT) for supervisions of tuberculosis (TB) treatment. We conducted a meta-analysis of implementation feedback obtained from people with TB and health care workers (HCWs) involved in TB REACH Wave 6-funded DAT evaluation projects. …”

Tun increases mitochondrial fission, inflammatory cell infiltration, and decreased ER-mitochondria interaction in neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

“…The decreased expressions of GRP75 (0.5±0.2-fold, p = 0.006767, n = 5) and acyl-CoA synthetase long-chain family member 4 (ASCL4; 0.3±0.1-fold, p<0.001, n = 5) indicate a decreased interaction between ER and mitochondria by Tun. …”

A647D decreased mexiletine sensitivity of P1332L when coexpressed. by Jie Liu (15128)

CD8+ T-cell interferon-gamma production and proliferation is decreased in <i>T</i>. <i>gondii</i>-infected HD mice. by David W. Donley (3111198)

“…<i>gondii</i> bradyzoites or vehicle at 5-weeks of age and sacrificed at 15 dpi. Cells were stimulated <i>ex-vivo</i> with <i>T</i>. …”

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”

S1 Data - by Jordan A. Gunning (18143970)

“…Specifically, total immune cells (CD45+) decrease at days 2 and 5 following IR, macrophages (F4/80+CD11b+) decrease at day 2 and 5 and increase at day 30, while neutrophils (Ly6G+CD11b+) significantly increase at day 30 following IR. …”

Rate of SARS-CoV-2 positive diagnostic tests in follow-up (April 30th, 2020 through April 30th, 2021) stratified by index SARS-CoV-2 infection status with rate ratio and hazard rat... by Shannon L. Reynolds (14822662)